Has Anil Potti, MD received payments from drug or device companies?

Yes. Drug and device makers reported $6,088 in general payments to Anil Potti, MD across 340 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anil Potti, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anil Potti, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anil Potti, MD

Hematology & Oncology · Grand Forks, NDNPI 1427122266

Payments from drug & device makers

$6,088in general payments, 2019–2025

Across 340 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$684
Johnson & Johnson$376
Pfizer$344
Merck$275
Astellas Pharma US Inc$270
Novartis$215
plus $4K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	39	$684
Johnson & Johnson(2 entities)	21	$376
Pfizer	12	$344
Merck	16	$275
Astellas Pharma US Inc	15	$270
Novartis	13	$215
Eisai Inc.	10	$202
Exelixis Inc.	8	$201
Daiichi Sankyo Inc.	11	$201
Bristol Myers Squibb	11	$189
Myriad Genetic Laboratories, Inc.	11	$173
Amgen	5	$158
Seagen Inc.	11	$157
Lilly USA, LLC	10	$155
GSK	8	$136
Gilead(2 entities)	8	$129
EMD Serono, Inc.	7	$113
Genentech USA, Inc.	8	$109
Tersera Therapeutics LLC	3	$97
Incyte Corporation	7	$93
Bayer	7	$93
Acrotech Biopharma Inc.	3	$76
Jazz Pharmaceuticals Inc.	4	$75
Karyopharm Therapeutics Inc.	4	$69
Boehringer Ingelheim	4	$67
Takeda Pharmaceuticals U.S.A., Inc.	3	$65
Puma Biotechnology, Inc.	4	$65
Taiho Oncology, Inc.	4	$63
E.r. Squibb & Sons, L.L.C.	3	$55
ADC Therapeutics America, Inc.	3	$55
Ipsen Biopharmaceuticals, Inc	3	$52
Pharmacyclics LLC, An Abbvie Company	3	$52
Regeneron Healthcare Solutions, Inc.	2	$51
Pharmacosmos Therapeutics Inc.	3	$48
AbbVie	3	$47
Coherus Oncology, Inc.	2	$47
Sanofi	3	$46
Deciphera Pharmaceuticals Inc.	2	$45
AVEO Pharmaceuticals, Inc.	3	$42
Mirati Therapeutics, Inc.	2	$39
Epizyme, Inc.	3	$39
Rigel Pharmaceuticals, Inc.	3	$38
Clovis Oncology, Inc.	2	$36
G1 Therapeutics, Inc.	2	$35
Sobi, Inc	2	$35
Pharmaessentia USA Corporation	2	$31
Beigene USA, Inc.	2	$30
EUSA Pharma (US) LLC	2	$29
Agios Pharmaceuticals, Inc.	2	$27
Genmab U.S., Inc.	1	$23
Kyowa Kirin, Inc.	1	$23
Spectrum Pharmaceuticals Inc.	1	$22
Tempus AI, Inc	1	$21
Janssen Scientific Affairs, LLC	1	$20
Amneal Pharmaceuticals LLC	1	$19
Pharmaand GmbH	1	$19
Tolmar Pharmaceuticals, Inc.	1	$19
Novocure Inc.	1	$19
Springworks Therapeutics, Inc.	1	$18
Octapharma USA, Inc.	1	$17

How this compares

$6,088 in reported general payments places this provider in the 65th percentile of 35 hematology & oncology providers in North Dakota.

See all hematology & oncology providers in North Dakota →

Medicare billing

Part B allowed, 2024

$12,486,172

Medicare patients

632

Services billed

701,969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Grand Forks

Karine DarbinyanGrand Forks$21K
Kevin PanicoGrand Forks$65
Daniel WalshGrand Forks$41
Amit PanwalkarFargo$589K
Daniel AlmquistFargo$230K
Jarrett FailingFargo$136K
Mahendra GuptaFargo$106K
Thandiwe GrayBismarck$104K
Harish AhujaFargo$82K
Anu GabaFargo$61K

See the full list for North Dakota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →